Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0519 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0519 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.046 | 0.8698 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0321 | 0.5619 | 0.5619 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.046 | 0.8698 | 0.8159 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0519 | 1 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.0321 | 0.5619 | 0.5619 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0199 | 0.2927 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0519 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0519 | 1 | 1 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0258 | 0.423 | 0.423 |
Leishmania major | cytochrome P450 reductase, putative | 0.046 | 0.8698 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0199 | 0.2927 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0519 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0519 | 1 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.0321 | 0.5619 | 0.5619 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.046 | 0.8698 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0262 | 0.4317 | 0.4317 |
Leishmania major | p450 reductase, putative | 0.0519 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0519 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0519 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0199 | 0.2927 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0321 | 0.5619 | 0.5619 |
Treponema pallidum | flavodoxin | 0.0199 | 0.2927 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0199 | 0.2927 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0519 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0519 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.0199 | 0.2927 | 0.2927 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0519 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0519 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0199 | 0.2927 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0258 | 0.423 | 0.5 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0199 | 0.2927 | 0.2927 |
Chlamydia trachomatis | sulfite reductase | 0.0321 | 0.5619 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0519 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0519 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0258 | 0.423 | 0.5 |
Plasmodium vivax | flavodoxin domain containing protein | 0.046 | 0.8698 | 0.8159 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0519 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0321 | 0.5619 | 0.5619 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0519 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0519 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0519 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0519 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0519 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.2387 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.